CD274 and neoplasm: Results from a recent meta-analysis investigating the role of LAG3 as prognostic biomarker in several solid tumors, including TNBC, showed that high expression of LAG3 can be associated with favorable outcome, particularly in early stage tumor, also if there was a borderline statistical significance in their results, suggesting that the role of LAG3 as prognostic biomarker should be evaluated together with the expression of other biomarkers reflecting an active host immunity, such as PD-L1 and CD8 [139].